National Institutes of Health (NIH)
NEWS
More than two years into the COVID-19 pandemic, some experts, business leaders and government agencies are starting to prep for the next potential pandemic.
There are an estimated 2.3 million people living with Multiple Sclerosis and hundreds of thousands more undiagnosed, adding up to an annual cost of nearly $85 billion for care in the United States.
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
Moderna announced that the first participant has been dosed in a Phase I trial of its HIV trimer mRNA vaccine, mRNA-1574.
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
Dr. Julie L. Gerberding, Merck’s chief patient officer and executive vice president of population health and sustainability, is retiring from Merck after 12 years.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
JOBS
IN THE PRESS